Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma by Surasak Phuphanich et al.
ORIGINAL ARTICLE
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine
for patients with newly diagnosed glioblastoma
Surasak Phuphanich • Christopher J. Wheeler • Jeremy D. Rudnick • Mia Mazer • HongQian Wang •
Miriam A. Nun˜o • Jaime E. Richardson • Xuemo Fan • Jianfei Ji • Ray M. Chu • James G. Bender •
Elma S. Hawkins • Chirag G. Patil • Keith L. Black • John S. Yu
Received: 1 March 2012 / Accepted: 6 July 2012 / Published online: 31 July 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Background This study evaluated the safety and immune
responses to an autologous dendritic cell vaccine pulsed
with class I peptides from tumor-associated antigens
(TAA) expressed on gliomas and overexpressed in their
cancer stem cell population (ICT-107).
Methods TAA epitopes included HER2, TRP-2, gp100,
MAGE-1, IL13Ra2, and AIM-2. HLA-A1- and/or HLA-A2-
positive patients with glioblastoma (GBM) were eligible.
Mononuclear cells from leukapheresis were differentiated
into dendritic cells, pulsed with TAA peptides, and admin-
istered intradermally three times at two-week intervals.
Results Twenty-one patients were enrolled with 17 newly
diagnosed (ND-GBM) and three recurrent GBM patients
and one brainstem glioma. Immune response data on 15
newly diagnosed patients showed 33 % responders. TAA
expression by qRT-PCR from fresh-frozen tumor samples
showed all patient tumors expressed at least three TAA, with
75 % expressing all six. Correlations of increased PFS and
OS with quantitative expression of MAGE1 and AIM-2 were
observed, and a trend for longer survival was observed with
gp100 and HER2 antigens. Target antigens gp100, HER1,
and IL13Ra2 were downregulated in recurrent tumors from 4
HLA-A2? patients. A decrease in or absence of CD133
expression was seen in five patients who underwent a second
resection. At a median follow-up of 40.1 months, six of 16
ND-GBM patients showed no evidence of tumor recurrence.
Median PFS in newly diagnosed patients was 16.9 months,
and median OS was 38.4 months.
Conclusions Expression of four ICT-107 targeted anti-
gens in the pre-vaccine tumors correlated with prolonged
overall survival and PFS in ND-GBM patients. The goal of
targeting tumor antigens highly expressed on glioblastoma
cancer stem cells is supported by the observation of
decreased or absent CD133 expression in the recurrent
areas of gadolinium-enhanced tumors.
Keywords Dendritic cell immunotherapy  Cancer stem
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Introduction
Glioblastoma multiforme (GBM) is the most common
and malignant primary brain tumor [1]. Immunotherapy
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with dendritic cells (DCs) offers the potential for high
tumor-specific toxicity and sustained tumoricidal activity
[2–4]. DCs are the most potent antigen-presenting cells
and can be derived ex vivo from blood monocytes using
GM-CSF and IL-4 [5]. DC immunotherapy has been
studied in a wide variety of cancers including patients
with glioma [6–8]. Our previous immunotherapy trials
have demonstrated induction of tumor-specific immune
responses [2, 6, 9] that correlated with clinical outcomes
[2].
Cancer stem cells (CSCs) have recently been identi-
fied in human brain tumors [10, 11]. This minority cell
population demonstrates potent tumorigenicity in immu-
nodeficient animals and shares properties with their
normal stem cell counterparts, namely the expression of
CD133, the properties of self-renewal, and differentiation
into comprehensive neuronal and glial lineages [12].
CD133? CSCs in glioma are more radioresistant [13]
and chemoresistant [14] and have been correlated with
poor clinical outcome [15], and studies of recurrent
tumors have shown increased expression of CD133 [14,
16]. Vaccine studies in mice using lysates from CSC
showed superior protective immunity compared with
lysates from whole tumor [17, 18]. We thus pursued a
clinical strategy of DC vaccination targeting antigens
overexpressed on CSCs along with other known tumor-
specific antigens.
Tumor-associated antigens have been identified that are
expressed on GBM cells [19, 20] and overexpressed on the
CSC [17]. These include HER2/neu [19, 21], TRP-2 [19,
20, 22], and AIM-2 [19, 23]. Other known tumor antigens
have been shown to be expressed on GBM cells including
gp100 [19–21], MAGE1 [19, 21], and IL13Ra2 [19, 20,
24]. ICT-107 is an autologous vaccine consisting of patient
DC pulsed with six synthetic class I peptides from AIM-2,
MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2. We
report here the safety and biological responses of ICT-107
in patients with gliomas.
Patients and methods
Study design
This was an open-label, single-institution, single-arm,
phase I study with the primary endpoint to evaluate the
immunogenicity of ICT-107 and secondary endpoints of
safety and efficacy in patients with glioblastoma or brain-
stem glioma. ND-GBM patients with surgery, who had no
imaging of tumor progression after a standard treatment
with concurrent temozolomide (TMZ) and radiation ther-
apy, were eligible for vaccine therapy, and recurrent GBM
patients with a gross total resection were also eligible.
After explanation of the protocol, written informed consent
was obtained from patients before screening; the vaccine
was then prepared and administered intradermally in the
axilla region every 2 weeks for three consecutive doses
after the completion of radiation or surgery. A diagram of
the treatment schedule is shown in Fig. 1. Post-vaccine,
newly diagnosed patients received maintenance temozol-
omide chemotherapy following the last dose of vaccine and
recurrent patients received chemotherapy with or without
bevacizumab. Patients were monitored once a month by
neurological examination and every 2 months by magnetic
resonance imaging. Progressive disease was defined by
MacDonald criteria. This protocol was allowed by the US
FDA and the local institution review board at Cedars-Sinai
Medical Center.
Patient selection
Patients with newly diagnosed or recurrent GBM with a
gross total resection ([95 %) or brainstem glioma were
HLA-A1 or HLA-A2 positive (HLA typing done by low
resolution PCR-SSOP). Inclusion criteria included the
presence of at least one of the vaccine antigens on the
patient’s tumor, a Karnofsky score of at least 60 %, glu-
cocorticoid therapy with dexamethasone B4 mg/day, and
Fig. 1 Diagram of treatment
schedule and events
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normal baseline hematological parameters. Exclusion cri-
teria included pregnancy; severe pulmonary, cardiac, or
other systemic disease associated with an unacceptable
anesthetic or operative risk; presence of an acute infection
requiring active treatment; history of an autoimmune dis-
order or allergy to gentamicin; or prior history of other
malignancies, excluding basal cell carcinoma and benign
tumors. The extent of surgical resection was defined as
either complete resection, with no linear gadolinium
enhancement on T1 MRI image or sub-total resection in
which minimal residual nodules were observed.
Tumor characterization
Tumor samples collected from surgery were dissociated into
single-cell suspensions with trypsin–EDTA (Invitrogen,
Carlsbad, CA) for 30 min and frozen at -80 C. In some
samples, formalin-fixed paraffin-embedded (FFPE) samples
were evaluated. RT-PCR method and primers used to
quantitate expression of mRNA for MAGE1, gp100, HER2,
AIM-2, TRP-2, and CD133 were previously described [14,
17, 21–23]. IL13Ra2 primers were from Qiagen, Valencia,
CA. Data analysis was done by comparison with the GAPDH
control using the 2-DD CT method [25].
FFPE tumor samples were evaluated for MGMT meth-
ylation by MDxHealth (Liege, Belgium) using RT-PCR as
previously described [26] and PTEN immunohistochemistry
with PTEN antibody (Clone 6H2.1, Cascade Biosciences).
Immunoreactivity was detected and visualized with either an
Ultraview DAB or a Bond Refine DAB system and reviewed
by at least one board-certified neuropathologist.
Preparation of autologous vaccine
Monocytes were prepared from leukapheresis products by
adherence for 2 h at 37 C, and adherent cells were cul-
tured for 5 days in RPMI 1640 with 10 % autologous
serum supplemented with recombinant human granulo-
cyte–macrophage colony-stimulating factor (Berlex)
(800 units/ml) and interleukin-4 (R&D systems)
(500 units/ml). On Day 5, 50 ng/ml tumor necrosis factor-a
(R&D systems) was added for 3–4 days.
Peptides included HLA-A1 restricted, MAGE1(161)
EADPTGHSY, AIM-2(14) RSDSGQQARY, and HLA-A2
restricted, TRP-2(180) SVYDFFVWL, gp100(210M) IM-
DQVPFSV, HER2(773) VMAGVGSPYV and IL13Ra2
(345) WLPFGFILI (Clinalfa, La¨ufelfingen, Switzerland).
Cells from Day 8–9 cultures were cultured at 106/ml with
peptides (10 lg/ml per antigen) at 37/5 % CO2, 16–20 h.
Pulsed cells were resuspended at 1 9 107 cells/ml in
10 %DMSO/90 % autologous serum and 1.1 ml, dispensed
into 1.8 ml Nunc cryo tubes (Roskilde, Denmark), frozen at
1 C/min, and stored in the vapor phase of liquid nitrogen.
On culture Day 2, a media aliquot was tested for ste-
rility. A gram stain, sterile culture, mycoplasma, and LAL
endotoxin assay were performed on the final product before
administration.
Vaccine administration
The frozen dose was thawed rapidly in a 37 C water bath,
transferred into a 1 ml tuberculin syringe, and administered
intradermally at multiple sites in the axillary region. Patients
were monitored for 2 h post-immunization for any adverse
effects. Patients received pretreatment with 50 mg of
diphenhydramine and 650 mg of acetaminophen as needed.
Immune response methods
Pre- and post-vaccination (7 days prior to vaccination, and
56 days later: 5 weeks after administration of the third and
last vaccine), PBMCs were thawed and co-cultured with a
mixture of all immunizing peptides (10 lg/ml) in stimu-
lating medium (10 % FBS/RPMI? anti-CD28/CD49d) at
37 C for 7 days.
On Day 7, cultures were restimulated with peptides.
Brefeldin-A and monensin were added after 1 h, and the cells
were cultured five more hours. Washed cells were stained
with surface markers (CD8, clone OKT8; CD3, clone OKT3;
CD107a, clone eBioH4A3, IFNc, clone 4S.B3; TNFa,
MAb11; all eBioscience), resuspended in 1X PermiFlow
(Invirion) and stored at room temperature overnight. Intra-
cellular staining for IFNc and TNFa was performed and the
CD8?INFc? population quantified within both CD8hi and
CD8lo subpopulations, as recommended by Cancer Immu-
notherapy Consortium Immune Monitoring Panels[27],
using identical forward and side scatter gating in all samples
(Fig. 6). A proportion of vaccine-enhanced cytokine? CD8?
cells [(Ag stimulated/unstimulated CD8? post-vaccine) 7
(Ag stimulated/unstimulated CD8? pre-vaccine)] were used
to assess immune responsiveness. CD107a staining closely
paralleled that of IFNc and TNFa (not shown) and correlated
significantly with IFNc responses (r = 0.65 for all cyto-
kine?, and 0.932 for CD8hi gates; p = 0.01 and 0.001,
respectively). Patients with a 1.5-fold higher post-vaccine
than with pre-vaccine score were considered responders.
This protocol reproduced immune response results of pre-
vious autologous DC stimulation assays analyzed by quan-
titative PCR for IFNc production at Day 56 [2], without
requiring high volume blood collections for DC differenti-
ation (not shown).
Statistical analysis
Continuous variables were compared with Student’s t test
and categorical variables compared using Fisher’s exact
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test. Probability of survival was determined with SAS
software by the Kaplan–Meier method, using two-tailed
Mann–Whitney log-rank test exclusively to compare
groups. Pearson’s correlation coefficients (r values) were
calculated in Excel software. Standard errors (±) of the
mean were provided whenever appropriate. Significant
observations were considered for p \ 0.05.
Results
Patient characteristics
Twenty-one patients who were HLA-A1 and/or HLA-A2
positive, 16 males and 5 females, were enrolled between May
2007 and January 2010 (Table 1). There were 17 ND-GBM
patients (16 evaluable; one patient did not receive treatment),
three patients with recurrent GBM, and one with brainstem
glioma (Table 1). A total of 62 dendritic cell vaccinations
were administered. In general, the vaccinations were well
tolerated with only grade 1 or 2 adverse events (Table 2). The
median age was 52 years (range 26–79 years), and the
median Karnofsky score was 90 (range 70–100). ND-GBM
patients that subsequently progressed were treated with a
variety of additional therapies including bevacizumab, CPT-
11, dose-dense temozolomide and cediranib.
Tumor characterization
Pathological examination of tumors showed variable mor-
phologic features of glioblastoma multiforme (GBM).
MGMT methylation by PCR and PTEN expression by
immunohistochemistry were performed on the majority of
cases. (Table 3). MGMT methylation was observed in
60 % (6 of 10) of the newly diagnosed patients and in 47 %
(7 of 15) of all the patients with evaluable results. Six of
the newly diagnosed patients did not have samples avail-
able for testing or had invalid results. PTEN expression by
immunohistochemistry was retained in 8 of 15 (53 %)
newly diagnosed patients evaluated.
Expression of tumor-associated antigens using PCR
measurement of mRNA was assessed on fresh-frozen
samples from patient tumors. Previous studies have dem-
onstrated the protein expression of these antigens on pri-
mary tumors and GBM cell lines [19–23]. All patient
tumors expressed at least three of the antigens (Table 3).
Fourteen (74 %) tumors expressed all six antigens, two
(11 %) expressed five antigens, two (11 %) expressed four
antigens, and one tumor (5 %) expressed three antigens.
Quantitative expression of the TAA targeted by the
vaccine was analyzed in 13 ND-GBM patients for whom
these data were available. In this analysis, expression of
AIM-2 and MAGE1 was shown to be significantly
correlated with PFS and OS (Fig. 2) and expression of
HER2 and gp100 showed a trend toward longer PFS and
OS. Significant correlations were not observed with
IL13Ra2 and TRP-2. FFPE samples from second surgeries
in five patients were evaluated and compared with samples
from primary tumors. Studies comparing matching FFPE
and fresh-frozen samples with PCR measurement of anti-
gen expression (not shown) showed a lower sensitivity of
detection using FFPE samples resulting in samples that
were negative for expression. Figure 3 shows the expres-
sion of target antigens in primary and recurrent tumors
from four HLA-A2 patients. Significant post-vaccine
downregulation (p = 0.023 by Fisher’s exact test) of the
A2 epitopes relative to upregulation was observed in three
patients where responses were positive. For comparison,






N = 19 N = 16
Gender
Male, N ( %) 15 (78.9) 12 (75.0)
Age in years




Mean (SD) 87 (9) 87 (10.1)
Median 90 90
Range 60–100 60–100










Extent of surgery, N (%)
Sub-total resection 4 4
Complete resection 15 12
First surgery to vaccine time
(months)
Mean (SD) 7.32 (5.69) 5.49 (2.52)
Median 5.19 4.52
Range 2.96–23.01 2.96–12.39
Corticosteroid therapy (%) 26.3 18.7
a Score collected at screening
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downregulation of the HLA-A1 target antigen AIM2 was
not significant in these patient tumors.
CD133, a non-targeted antigen expressed on the stem cell
fraction in gliomas and reported to be increased in recurrent
tumors [14, 16], was evaluated in FFPE samples from pri-
mary and recurrent tumors. In recurrent patients, CD133
expression in the recurrent tumor decreased by two logs in
one patient (#03) and became negative in the other (#08)
(Fig. 4). In newly diagnosed patients, one patient (#10) was
negative for CD133 in both the primary and recurrent tumor,
one patient (#09) showed a one-log decrease in CD133
expression, and the third patient (#19) was negative for
CD133 in the second surgical sample. This surgery per-
formed on patient #19 showed no evidence of tumor, and this
patient was considered not to have progressed.
Survival
For survival analysis, only the 16 newly diagnosed adult
GBM patients who received treatment were considered. No
patient was lost to follow-up. A summary of demographics,
survival, immune response, and KPS on individual newly
diagnosed patients is presented in Table 4. The progres-
sion-free survival (PFS) and overall survival rates (OS) are
presented in Table 5. The PFS time was 16.9 months, and a
two-year PFS rate was 43.8 % (95 %CI, 19.8–66.0). The
three-year overall survival rate was 55.6 % (95 %CI,
28.6–75.9). The median OS was 38.4 months with eight of
16 patients alive. Six patients showed no tumor recurrence
at 49 to 66 months. The Kaplan–Meier probability curves
of PFS and OS are shown in Fig. 5a and b, respectively. No
Table 2 Attributable adverse events
Event Number of patients (N = 11) Number of events (N = 12)
Grade 1 N (%) Grade 2 N (%) Total grade 1 and 2 Grade 1 N (%) Grade 2 N (%) Total grade 1 and 2
Diarrhea – 1 (9) 1 (9) – 1 (8) 1 (8)
Fatigue 3 (27) – 3 (27) 4 (33) – 4 (33)
Flushing 1 (9) – 1 (9) 1 (8) – 1 (8)
Pruritus 2 (18) – 2 (18) 2 (17) – 2 (17)
Rash 2 (18) – 2 (18) 2 (17) – 2 (17)
Redness on skin 1 (9) – 1 (9) 1 (8) – 1 (8)
Vomiting – 1 (9) 1 (9) – 1 (8) 1 (8)
Table 3 Characterization of tumor for newly diagnosed glioblastoma patients
Patient ID Ag expression on tumor (peptide HLA restriction) Biomarker characterization
HLA type AIM2 (A1) gp100 (A1) MAGE (A2) TRP-2 (A2) HER2 (A2) ILRa2 (A2) MGMT PTEN
2 A2? ? ? ? ? ? ? UnMet RETAINED
4 A1? ? ? ? ? ? ? UnMet N/A
6 A2? ? ? Wk ? ? ? Met RETAINED
7 A2? ? ? ? ? ? ? Met LOSS
9 A2? ? ? - ? - ? Met RETAINED
10 A2? ? ? Wk ? ? ? INV RETAINED
11 A2? ? ? ? ? ? ? UnMet LOSS
12 A2? ? ? Wk ? ? ? UnMet RETAINED
13 A1? ? Wk Wk ? ? ? NT LOSS
14 A1? ? ? - ? ? ? NT LOSS
15 A1? ? - ? ? ? ? INV RETAINED
16 A1 ? A2? ? ? Wk ? ? ? Met LOSS
17 A2? ? - Wk - ? - NT LOSS
18 A1? ? Wk Wk ? ? ? NT LOSS
19 A2? ? ? Wk ? ? ? Met RETAINED
20 A2? ? ? Wk ? ? ? Met RETAINED
Positive (?), negative (-), weak (Wk)
UnMet unmethylated, Met methylated, INV invalid results, NT not tested
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difference in survival was observed between HLA-A2?
and HLA-A1? patients.
Development of systemic type I cytokine responses
and correlation with survival
IFNc and TNFa production was quantified according to
‘‘Patients and methods’’ (Day -7 and Day 56, respec-
tively). TNFa responses were highly correlated with IFNc
responses (r = 0.92; p = 0.001). Individual patient
immune response indexes are presented in Table 4 with
representative gating and responder IFNc plots presented
in Fig. 6. For vaccine response determination, post-vac-
cine values were divided by pre-vaccine values, with a
C.5-fold increase over pre-vaccine constituting post-vac-
cine response enhancement. The baseline for the pre-
vaccine calculation is cytokine production in the absence
of peptide with C.5-fold increased production before
vaccination constituting and endogenous antigen-directed
response as previously published [2, 6]. Antigen-specific
cytokine production was attempted by co-staining with
immunizing epitope-specific pHLA multimers (NCI), but
failed to exhibit convincing pHLA staining in any patient
(not shown). Although Day 56 was previously reported to
represent the peak response time in similar DC trials [2],
immune responsiveness was assessed at later time points
in patients with long survival at Day 56. Of these six
patients, only one exhibited a previously undetected
vaccine response approaching a 1.5-fold increase after
Day 56 (1.46-fold; not shown). Analysis of immune
responses from samples 7 days before vaccine adminis-
tration and compared with samples 56 days after the first
vaccine showed 5 of 15 GBM patients tested (33 %)
exhibited a positive vaccine response of [.5-fold
increase. PFS exhibited a trend toward better survival in
responders relative to non-responders, as well as
increased long-term and overall survivors, but these did
not reach significance.
Discussion
The dendritic cell vaccine evaluated was shown to be non-
toxic in this study. Survival analysis of the newly diag-
nosed patients demonstrating a 16.9-month PFS, together a
median overall survival of 38.4 months, suggests that
Fig. 2 a Correlation of quantitative antigen expression on primary
tumor from ND patients with progression-free survival (n = 13).
Logarithmic plots of antigen expression determined by qRT-PCR (see
‘‘Patients and methods’’) showed correlations of increasing antigen
expression with longer progression-free survival times (PFS). Antigen
expression was measured from fresh-frozen samples and calculated
relative to GAPDH. b Correlation of quantitative antigen expression
on primary tumor from ND patients with overall survival (n = 13).
Logarithmic plots of antigen expression determined by qRTPCR (see
‘‘Patients and methods’’) showed correlations of increasing antigen
expression with longer overall survival time (OS)
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vaccination following conventional treatment may be
associated with a clinically relevant response. Enhance-
ment of a type I immune response in 33 % of these patients
is comparable to previous DC vaccine trials. Vaccine
responders exhibited a non-significant trend toward
increased progression-free survival, but not overall sur-
vival. Recent clinical trials in glioma patients reported
favorable safety and clinical outcomes following DC vac-
cination [3, 28]. In one trial, a significant correlation
between IL-12 produced by DCs in the vaccine with
increased time to progression in treated patients was
observed [28]. Although no similar correlation of effector
T-cell responses and clinical metrics was observed here, as
we previously reported [2], the apparent clinical improve-
ment of these patients corroborates that type I cytokine–
enhancing DC vaccination may benefit GBM patients.
Our analysis did not reveal significant correlations of
vaccine-associated type I cytokine levels within survival
metrics, as in previous brain tumor vaccine trials. Although
it is possible that with further follow-up some of these
metrics may yet reach significance, this continues a pre-
dominant trend of poor correlation of immune and survival
metrics in cancer vaccine trials. This may be due to inac-
curate determination of clinically relevant immune
responder status by ex vivo assays, but could also reflect
local inhibition of peripherally activated immune effectors
at the tumor site. In the case of general assay inaccuracy,
long- and short-term survivors are expected to be essen-
tially evenly distributed among responders and non-
responders. In the case of local inhibition, however, long-
term survivors are expected to be disproportionately rep-
resented within immune responders, with short-term sur-
vivors essentially evenly distributed, as is evident in our
study. Thus, local inhibition may affect the lack of
immune-survival correlation more than assay inaccuracy in
this study, although it is also possible that our assay may
preferentially but imperfectly identify clinically relevant
Fig. 3 Downregulation of target antigens in recurrent tumors from
HLA-A2? patients. Antigen expression was from FFPE samples and
calculated relative to GADPH. Significant downregulation post-
vaccine of A2 epitopes gp100, HER2, and IL13Ra2 relative to
upregulations was observed (p = 0.023, Fisher’s exact test). Down-
regulation of the HLA-A1 antigen, AIM2, was not significant
(p = 0.21) in these patients
Fig. 4 CD133 expression by RT-PCR in primary tumor and samples
from subsequent surgeries from newly diagnosed and recurrent
patients. Expression is from FFPE samples and calculated relative to
GADPH as described in ‘‘Patients and methods’’. The sample for
Patient 19 was negative for tumor
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immune responders. One strategy to address this is to
identify immune and surrogate biomarkers locally at the
tumor site and compare them to both peripheral response
status and clinical outcomes. Gene and protein analysis of
pre- and post-vaccine gliomas is currently underway to
identify candidate biomarkers for this approach.
Evaluation of target tumor antigen expression on patient
tumors by PCR showed that all patients expressed at least
three of the immunizing antigens, with 74 % of the patients
expressing all six. Moreover, quantified expression of
AIM-2 and MAGE1 on primary tumors correlated signifi-
cantly with longer PFS, while expression of AIM-2 and
MAGE1 correlated significantly with longer PFS and OS.
The level of expression reported here is consistent with a
previous study of GBM tumors [19].
Multiple epitopes targeted by our vaccine are derived
from proteins reported to be overexpressed on the cancer
stem cell fraction of GBM [17]. Moreover, loss of targeted
antigen reportedly correlates with glioma vaccine efficacy
[29]. Consistent with those findings, we observed a
downregulation of three of the HLA-A2 target antigens was
observed in four HLA-A2? patients where recurrent
tumors were available. We also examined loss of expres-
sion of CD133, a non-targeted antigen expressed on the
stem cell fraction in gliomas, to evaluate whether stem-like
glioma cells might be selectively targeted by the vaccine.
Although only a few patients were studied, tumors from
post-vaccine resections showed a decrease in or loss of
CD133 expression relative to their pre-vaccine
Table 4 Demographics and survival and immune response for newly diagnosed glioblastoma patients













2 64 M R temporal parietal Complete 11.15 28.60 0.76, 0.65 100
4 46 M L frontal Complete 60.95a 60.95a 1.74, 1.15 90
6 56 F L temporal Complete 66.51a 66.51a 1.03, 0.96 100
7 61 F R frontal Complete 60.10a 60.10a 3.58c 90
9 51 M R anterior temporal Complete 6.87 19.53 0.67, 0.95 90
10 47 M L frontoparietal Complete 15.98 53.03a 1.49, 1.00 90
11 53 F R temporal Sub-total 12.62 25.91 0.61, 0.74 90
12 65 M R temporal Complete 8.25 22.55 0.43, 0.49 90
13 60 M L temporal Complete 29.0 38.37 2.19, 0.53 90
14 44 M R temporoparietal Complete 49.38* 49.38* 0.46, 1.73 80
15 34 M R parietal Complete 48.66a 48.66a 0.43, 0.82 90
16 63 M L parietal Sub-total 17.72 32.42 1.07, 1.18 60
17 79 M R frontal Sub-total 11.28 15.98 0.62, 1.83 70
18 52 F Bifrontal Complete 8.88 33.99 1.21, 1.01 90
19 48 M L Frontal Complete 47.64a 47.64a 0.56, 0.91 80
20 62 M L Temporal Sub-total 7.27 41.82a NT 90
a Progression/mortality has not been observed for these patients
b IFNchi = IFNc? in CD8hi gate; IFNclo = IFNc? in CD8lo gate
c Fresh CD8? cells, no in vitro stimulation
d At screening
Bold values indicate positive immune response greater than 1.5
Table 5 Progression-free and overall survival in months for newly
diagnosed glioblastoma patients
Time in months % Survival (95 % CI)
Progression-free survival
6 100
12 62.5 (34.9, 81.1)
18 43.8 (19.8, 66.0)
24 43.8 (19.8, 66.0)




18 93.7 (63.2, 99.1)
24 80.3 (58.6, 96.7)
36 55.6 (28.6, 75.9)
Median 38.4 (25.9, 40.7)
CI confidence interval
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counterparts. This finding is intriguing because previous
studies from our group [14] and others [16] have consis-
tently shown increased expression of CD133 in recurrent
tumors, including in those recurring after tumor lysate–
loaded DC vaccination [30]. Although the relevance of
these inconsistent increases to cancer stem and/or endog-
enous neural stem cells, as well as to clinical disease
course, is not entirely clear [14, 16], the observed
decreased expression of CD133 is consistent with
preferential vaccine-mediated elimination of CD133? cells
from recurrent tumors [17].
In conclusion, this phase I study of ICT-107 demon-
strated the feasibility, safety, and bioactivity of a TAA-
pulsed dendritic cell vaccine for patients with glioblas-
toma. Expression of AIM2 and MAGE1 antigens in the
pre-vaccine tumors correlated with prolonged survival as
measured by PFS and OS in ND-GBM patients, while
expression of HER2 and gp100 showed a trend toward
Fig. 5 a Kaplan–Meier estimates of progression-free survival for
newly diagnosed patients (n = 16). Dotted lines illustrate the 95 %
confidence intervals, and hash marks denote censored patients.
b Kaplan–Meier estimates of overall survival for newly diagnosed
patients (n = 16). Dotted lines illustrate the 95 % confidence
intervals, and hash marks denote censored patients
Fig. 6 Gating strategy for intracellular cytokine analysis in CD8?
cells. Identical gain and gating was employed on all stimulated,
unstimulated, pre-, and post-vaccine plots prior to analysis.
Representative antigen-stimulated, post-vaccine plots from a IFNc-
responsive patient (#4) are shown
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longer PFS and OS. With these encouraging results, a
randomized, placebo-controlled, phase II trial is underway.
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